Acetazolamide-induced inhibition of carbonic anhydrase influences energy metabolism and respiratory work in healthy subjects.
To assess the usefulness of acetazolamide in weaning a patient from a respirator, we monitored the changes in the respiratory quotient ratio (RQ ratio), the ventilation volume (VE; l/min.), carbon dioxide elimination (VCO2; ml/min.), the oxygen consumption (VO2; ml/min.) and the metabolic energy expenditure (EE; Cal/day) for 6 hours before (baseline) and after the intravenous administration of acetazolamide, 6 mg/kg, in 12 healthy adult volunteers. The RQ ratio decreased significantly from 0.88 to 0.82 after the injection of acetazolamide, 6 mg/kg, and remained below baseline throughout the 6 hours of observation. VCO2 decreased significantly and VE increased significantly after acetazolamide administration. There were no significant changes in VO2 or EE. The RQ ratio increased only slightly, from 0.85 to 0.87, in the control group (no acetazolamide). No significant changes in VCO2 or VE were observed in the control group. Findings suggest that acetazolamide may alter the main pathway of energy metabolism from being carbohydrate-dominant to being fat-dominant, with a resulting fall in CO2 production to maintain the adequate work of ventilation. The inhibition of carbonic anhydrase by acetazolamide may be useful in reducing respiratory work in a patient who is weaned from a respirator.
Hirahara
K
K
Department of Emergency Medicine, School of Medicine, Saga Medical College, Japan.
Taki
K
K
Tomita
S
S
Yamada
T
T
D000086:Acetazolamide / Q000494:pharmacology*; D000328:Adult; D002245:Carbon Dioxide / Q000378:metabolism; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology*; D004734:Energy Metabolism / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects; D014939:Work of Breathing / Q000187:drug effects*
D002257:Carbonic Anhydrase Inhibitors; D002245:Carbon Dioxide; D000086:Acetazolamide